Global Brigatinib API 麻豆原创 Growth 2024-2030

Publication ID:

LPI11241821

Publication Date:

November 18, 2024

Pages:

106

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Brigatinib is an active pharmaceutical ingredient (API) used for the treatment of non-small cell lung cancer (NSCLC) with ALK gene mutations.It is a selective ALK inhibitor that works by blocking the ALK protein.
The global Brigatinib API market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淏rigatinib API Industry Forecast鈥� looks at past sales and reviews total world Brigatinib API sales in 2023, providing a comprehensive analysis by region and market sector of projected Brigatinib API sales for 2024 through 2030. With Brigatinib API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Brigatinib API industry.
This Insight Report provides a comprehensive analysis of the global Brigatinib API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Brigatinib API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Brigatinib API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Brigatinib API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Brigatinib API.
United States market for Brigatinib API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Brigatinib API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Brigatinib API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Brigatinib API players cover Dr. Reddy鈥檚 Laboratories, Vitasv Pharma And Chemical, LGC, Cayman Chemical, Conscientia Industrial, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Brigatinib API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
笔耻谤颈迟测鈮�99%
Purity<99%
Segmentation by Application:
Online Sales
Offline Sales
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Dr. Reddy鈥檚 Laboratories
Vitasv Pharma And Chemical
LGC
Cayman Chemical
Conscientia Industrial
Manus Aktteva Biopharma LLP
Selleck
Shandong Sihuan Pharmaceutical
Anqing benro Pharmaceutical
Vasudha Pharma
Hefei 麻豆原创 Sunshine Pharmaceutical Technology
Sandoo Pharmaceuticals and Chemicals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Brigatinib API market?
What factors are driving Brigatinib API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Brigatinib API market opportunities vary by end market size?
How does Brigatinib API break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Brigatinib API Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Brigatinib API by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Brigatinib API by Country/Region, 2019, 2023 & 2030
2.2 Brigatinib API Segment by Type
2.2.1 笔耻谤颈迟测鈮�99%
2.2.2 Purity<99%
2.3 Brigatinib API Sales by Type
2.3.1 Global Brigatinib API Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Brigatinib API Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Brigatinib API Sale Price by Type (2019-2024)
2.4 Brigatinib API Segment by Application
2.4.1 Online Sales
2.4.2 Offline Sales
2.5 Brigatinib API Sales by Application
2.5.1 Global Brigatinib API Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Brigatinib API Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Brigatinib API Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Brigatinib API Breakdown Data by Company
3.1.1 Global Brigatinib API Annual Sales by Company (2019-2024)
3.1.2 Global Brigatinib API Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Brigatinib API Annual Revenue by Company (2019-2024)
3.2.1 Global Brigatinib API Revenue by Company (2019-2024)
3.2.2 Global Brigatinib API Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Brigatinib API Sale Price by Company
3.4 Key Manufacturers Brigatinib API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Brigatinib API Product Location Distribution
3.4.2 Players Brigatinib API Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Brigatinib API by Geographic Region
4.1 World Historic Brigatinib API 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Brigatinib API Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Brigatinib API Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Brigatinib API 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Brigatinib API Annual Sales by Country/Region (2019-2024)
4.2.2 Global Brigatinib API Annual Revenue by Country/Region (2019-2024)
4.3 Americas Brigatinib API Sales Growth
4.4 APAC Brigatinib API Sales Growth
4.5 Europe Brigatinib API Sales Growth
4.6 Middle East & Africa Brigatinib API Sales Growth
5 Americas
5.1 Americas Brigatinib API Sales by Country
5.1.1 Americas Brigatinib API Sales by Country (2019-2024)
5.1.2 Americas Brigatinib API Revenue by Country (2019-2024)
5.2 Americas Brigatinib API Sales by Type (2019-2024)
5.3 Americas Brigatinib API Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Brigatinib API Sales by Region
6.1.1 APAC Brigatinib API Sales by Region (2019-2024)
6.1.2 APAC Brigatinib API Revenue by Region (2019-2024)
6.2 APAC Brigatinib API Sales by Type (2019-2024)
6.3 APAC Brigatinib API Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Brigatinib API by Country
7.1.1 Europe Brigatinib API Sales by Country (2019-2024)
7.1.2 Europe Brigatinib API Revenue by Country (2019-2024)
7.2 Europe Brigatinib API Sales by Type (2019-2024)
7.3 Europe Brigatinib API Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Brigatinib API by Country
8.1.1 Middle East & Africa Brigatinib API Sales by Country (2019-2024)
8.1.2 Middle East & Africa Brigatinib API Revenue by Country (2019-2024)
8.2 Middle East & Africa Brigatinib API Sales by Type (2019-2024)
8.3 Middle East & Africa Brigatinib API Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Brigatinib API
10.3 Manufacturing Process Analysis of Brigatinib API
10.4 Industry Chain Structure of Brigatinib API
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Brigatinib API Distributors
11.3 Brigatinib API Customer
12 World Forecast Review for Brigatinib API by Geographic Region
12.1 Global Brigatinib API 麻豆原创 Size Forecast by Region
12.1.1 Global Brigatinib API Forecast by Region (2025-2030)
12.1.2 Global Brigatinib API Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Brigatinib API Forecast by Type (2025-2030)
12.7 Global Brigatinib API Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Dr. Reddy鈥檚 Laboratories
13.1.1 Dr. Reddy鈥檚 Laboratories Company Information
13.1.2 Dr. Reddy鈥檚 Laboratories Brigatinib API Product Portfolios and Specifications
13.1.3 Dr. Reddy鈥檚 Laboratories Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Dr. Reddy鈥檚 Laboratories Main Business Overview
13.1.5 Dr. Reddy鈥檚 Laboratories Latest Developments
13.2 Vitasv Pharma And Chemical
13.2.1 Vitasv Pharma And Chemical Company Information
13.2.2 Vitasv Pharma And Chemical Brigatinib API Product Portfolios and Specifications
13.2.3 Vitasv Pharma And Chemical Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Vitasv Pharma And Chemical Main Business Overview
13.2.5 Vitasv Pharma And Chemical Latest Developments
13.3 LGC
13.3.1 LGC Company Information
13.3.2 LGC Brigatinib API Product Portfolios and Specifications
13.3.3 LGC Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 LGC Main Business Overview
13.3.5 LGC Latest Developments
13.4 Cayman Chemical
13.4.1 Cayman Chemical Company Information
13.4.2 Cayman Chemical Brigatinib API Product Portfolios and Specifications
13.4.3 Cayman Chemical Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Cayman Chemical Main Business Overview
13.4.5 Cayman Chemical Latest Developments
13.5 Conscientia Industrial
13.5.1 Conscientia Industrial Company Information
13.5.2 Conscientia Industrial Brigatinib API Product Portfolios and Specifications
13.5.3 Conscientia Industrial Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Conscientia Industrial Main Business Overview
13.5.5 Conscientia Industrial Latest Developments
13.6 Manus Aktteva Biopharma LLP
13.6.1 Manus Aktteva Biopharma LLP Company Information
13.6.2 Manus Aktteva Biopharma LLP Brigatinib API Product Portfolios and Specifications
13.6.3 Manus Aktteva Biopharma LLP Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Manus Aktteva Biopharma LLP Main Business Overview
13.6.5 Manus Aktteva Biopharma LLP Latest Developments
13.7 Selleck
13.7.1 Selleck Company Information
13.7.2 Selleck Brigatinib API Product Portfolios and Specifications
13.7.3 Selleck Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Selleck Main Business Overview
13.7.5 Selleck Latest Developments
13.8 Shandong Sihuan Pharmaceutical
13.8.1 Shandong Sihuan Pharmaceutical Company Information
13.8.2 Shandong Sihuan Pharmaceutical Brigatinib API Product Portfolios and Specifications
13.8.3 Shandong Sihuan Pharmaceutical Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Shandong Sihuan Pharmaceutical Main Business Overview
13.8.5 Shandong Sihuan Pharmaceutical Latest Developments
13.9 Anqing benro Pharmaceutical
13.9.1 Anqing benro Pharmaceutical Company Information
13.9.2 Anqing benro Pharmaceutical Brigatinib API Product Portfolios and Specifications
13.9.3 Anqing benro Pharmaceutical Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Anqing benro Pharmaceutical Main Business Overview
13.9.5 Anqing benro Pharmaceutical Latest Developments
13.10 Vasudha Pharma
13.10.1 Vasudha Pharma Company Information
13.10.2 Vasudha Pharma Brigatinib API Product Portfolios and Specifications
13.10.3 Vasudha Pharma Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Vasudha Pharma Main Business Overview
13.10.5 Vasudha Pharma Latest Developments
13.11 Hefei 麻豆原创 Sunshine Pharmaceutical Technology
13.11.1 Hefei 麻豆原创 Sunshine Pharmaceutical Technology Company Information
13.11.2 Hefei 麻豆原创 Sunshine Pharmaceutical Technology Brigatinib API Product Portfolios and Specifications
13.11.3 Hefei 麻豆原创 Sunshine Pharmaceutical Technology Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Hefei 麻豆原创 Sunshine Pharmaceutical Technology Main Business Overview
13.11.5 Hefei 麻豆原创 Sunshine Pharmaceutical Technology Latest Developments
13.12 Sandoo Pharmaceuticals and Chemicals
13.12.1 Sandoo Pharmaceuticals and Chemicals Company Information
13.12.2 Sandoo Pharmaceuticals and Chemicals Brigatinib API Product Portfolios and Specifications
13.12.3 Sandoo Pharmaceuticals and Chemicals Brigatinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Sandoo Pharmaceuticals and Chemicals Main Business Overview
13.12.5 Sandoo Pharmaceuticals and Chemicals Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.